RVL Pharmaceuticals plc to Discuss First Quarter 2022 Financial Results and Provide Commercial Update

Rhea-AI Summary

RVL Pharmaceuticals plc (Nasdaq: RVLP) is set to release its first quarter 2022 financial results and provide a commercial update on May 12, 2022, before U.S. markets open. The conference call will feature CEO Brian Markison and other executives discussing key financial metrics and business strategies. RVL focuses on underserved patient populations in ocular and medical aesthetics, currently commercializing UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution) 0.1%. Investors can access the live webcast and replay on the company’s website.

Positive

• Scheduled commercial update may indicate strong performance metrics.
• Focus on underserved markets could drive growth opportunities.

Negative

• None.

Conference call to be held Thursday, May 12, 2022, at 8:30 a.m. ET

BRIDGEWATER, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its first quarter 2022 financial results and provide a commercial update on Thursday, May 12, 2022, before U.S. financial markets open.

Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Mike DePetris, Interim Chief Financial Officer, will host a conference call as follows:

Date		Thursday, May 12, 2022
Time		8:30 a.m. ET
Toll free (U.S.)		866-342-8591
International		203-518-9713
Conference ID		RVLPQ122
Webcast (live and replay)		www.rvlpharma.com under the “Investors & News” section

About RVL Pharmaceuticals plc
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ^® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.

Investor and Media Relations for RVL Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

When will RVL Pharmaceuticals release its Q1 2022 financial results?

RVL Pharmaceuticals will release its Q1 2022 financial results on May 12, 2022.

What is the ticker symbol for RVL Pharmaceuticals?

The ticker symbol for RVL Pharmaceuticals is RVLP.

Who will host the conference call for RVL Pharmaceuticals?

The conference call will be hosted by CEO Brian Markison, COO James Schaub, and Interim CFO Mike DePetris.

How can I access the RVL Pharmaceuticals conference call?

You can access the conference call by calling 866-342-8591 (U.S.) or 203-518-9713 (International), or by visiting the company’s website for the webcast.

What product is RVL Pharmaceuticals currently commercializing?

RVL Pharmaceuticals is currently commercializing UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.